Loading...
Montelukast is a leukotriene-receptor antagonist approved for asthma and allergic rhinitis. In 2020, after reviewing postmarketing reports of anxiety, sleep disturbances, depression, and suicidality with montelukast, the U.S. FDA required that a warning about neuropsychiatric events be placed on montelukast's label. Subsequent studies yielded conflicting results about neuropsychiatric events associated with leukotriene-receptor antagonists. Now, two large retrospective studies offer more information.
Researchers used a Korean claims database to evaluate 145,000 adults with asthma or allergic rhinitis and neuropsychiatric events, and 145,000 matched controls with asthma or allergic rhinitis who didn't have neuropsychiatric events. Montelukast…